Ifm_05-may 2022 -

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. IFM_05-May 2022

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. The study demonstrated a clear overall survival benefit